Latanoprost-Loaded Nanotransfersomes Designed for Scalp Administration Enhance Keratinocytes Proliferation
Por:
Pena-Rodriguez, E, García-Vega L, Lajarin Reinares M, Pastor-Anglada M, Perez-Torras S and Fernandez-Campos, F
Publicada:
1 may 2023
Ahead of Print:
1 dic 2022
Resumen:
Latanoprost (LAT) has been shown to have a hypertrichotic effect, which makes it a promising candidate for alopecia treatments. For the first time, LAT has been encapsulated in nanotransfersomes in order to increase its efficacy. Ex vivo skin biodistribution was studied by confocal laser microscopy both in human scalp and pig skin. Results showed that nanotransfersomes increase the penetration of two different fluorochromes, with similar patterns in both species, compared with fluorochrome solutions containing no nanotransfersomes. Nanotransfersomes were stable under accelerated conditions (40 degrees C/75% RH) and long-term conditions (25 degrees C/60% RH) for up to 1 year, with no differences in vesicle size and polydispersity when LAT was loaded. Nanotransfersomes increased the LAT cell proliferation effect in HaCaT cell via MAPK signaling pathway. Collectively, our results demonstrate LAT-nanotransfersomes formulation could be a promising therapy for hair growth disorders.
Filiaciones:
Pena-Rodriguez, E:
Laboratory Reig Jofre, R&D Department, 08970Sant Joan Despi, Barcelona, Spain
R&D Dept, Lab Reig Jofre, Barcelona 08970, Spain
García-Vega L:
Molecular Pharmacology and Experimental Therapeutics, Department of Biochemistry and Molecular. Biomedicine, Institute of Biomedicine (IBUB), University of Barcelona (IBUB), 08028Barcelona, Spain
Biomedical Research Networking Center in Hepatic and Digestive Diseases (CIBEREHD), Carlos III Health Institute, 28029Madrid, Spain
Sant Joan de Déu Research Institute (IR SJD-CERCA) Esplugues de Llobregat, 08950Barcelona, Spain
Univ Barcelona IBUB, Inst Biomed IBUB, Dept Biochem & Mol Biomed, Mol Pharmacol & Expt Therapeut, Barcelona 08028, Spain
Carlos III Hlth Inst, Biomed Res Networking Ctr Hepat & Digest Dis CIBE, Madrid 28029, Spain
St Joan de Deu Res Inst IR SJD CERCA, Barcelona 08950, Spain
Lajarin Reinares M:
Laboratory Reig Jofre, R&D Department, 08970Sant Joan Despi, Barcelona, Spain
Pastor-Anglada M:
Molecular Pharmacology and Experimental Therapeutics, Department of Biochemistry and Molecular. Biomedicine, Institute of Biomedicine (IBUB), University of Barcelona (IBUB), 08028Barcelona, Spain
Biomedical Research Networking Center in Hepatic and Digestive Diseases (CIBEREHD), Carlos III Health Institute, 28029Madrid, Spain
Sant Joan de Déu Research Institute (IR SJD-CERCA) Esplugues de Llobregat, 08950Barcelona, Spain
Univ Barcelona IBUB, Inst Biomed IBUB, Dept Biochem & Mol Biomed, Mol Pharmacol & Expt Therapeut, Barcelona 08028, Spain
Carlos III Hlth Inst, Biomed Res Networking Ctr Hepat & Digest Dis CIBE, Madrid 28029, Spain
St Joan de Deu Res Inst IR SJD CERCA, Barcelona 08950, Spain
Perez-Torras S:
Molecular Pharmacology and Experimental Therapeutics, Department of Biochemistry and Molecular. Biomedicine, Institute of Biomedicine (IBUB), University of Barcelona (IBUB), 08028Barcelona, Spain
Biomedical Research Networking Center in Hepatic and Digestive Diseases (CIBEREHD), Carlos III Health Institute, 28029Madrid, Spain
Sant Joan de Déu Research Institute (IR SJD-CERCA) Esplugues de Llobregat, 08950Barcelona, Spain
Univ Barcelona IBUB, Inst Biomed IBUB, Dept Biochem & Mol Biomed, Mol Pharmacol & Expt Therapeut, Barcelona 08028, Spain
Carlos III Hlth Inst, Biomed Res Networking Ctr Hepat & Digest Dis CIBE, Madrid 28029, Spain
St Joan de Deu Res Inst IR SJD CERCA, Barcelona 08950, Spain
Fernandez-Campos, F:
Laboratory Reig Jofre, R&D Department, 08970Sant Joan Despi, Barcelona, Spain
R&D Dept, Lab Reig Jofre, Barcelona 08970, Spain
Green Submitted, hybrid
|